Arizona State Retirement System continued to hold its position in shares of STERIS plc (NYSE:STE) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 38,300 shares of the company’s stock at the end of the third quarter. Arizona State Retirement System’s holdings in STERIS plc were worth $2,800,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also made changes to their positions in the company. BB&T Corp raised its position in shares of STERIS plc by 10.5% in the third quarter. BB&T Corp now owns 82,979 shares of the company’s stock worth $6,066,000 after buying an additional 7,892 shares during the period. Quantitative Investment Management LLC acquired a new position in shares of STERIS plc during the third quarter worth about $1,359,000. First Trust Advisors LP raised its position in shares of STERIS plc by 4.8% in the third quarter. First Trust Advisors LP now owns 7,524 shares of the company’s stock worth $550,000 after buying an additional 348 shares during the period. Public Employees Retirement Association of Colorado raised its position in shares of STERIS plc by 3.8% in the third quarter. Public Employees Retirement Association of Colorado now owns 895,757 shares of the company’s stock worth $65,480,000 after buying an additional 32,382 shares during the period. Finally, Stratos Wealth Partners LTD. acquired a new position in shares of STERIS plc during the third quarter worth about $1,567,000. Hedge funds and other institutional investors own 91.09% of the company’s stock.
Shares of STERIS plc (NYSE:STE) traded up 0.42% on Friday, hitting $67.08. The stock had a trading volume of 102,736 shares. STERIS plc has a 12 month low of $61.38 and a 12 month high of $78.77. The stock has a market cap of $5.72 billion, a P/E ratio of 33.86 and a beta of 1.30. The firm has a 50 day moving average of $67.49 and a 200 day moving average of $69.49.
STERIS plc (NYSE:STE) last released its earnings results on Wednesday, November 2nd. The company reported $0.89 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.90 by $0.01. The company earned $646.40 million during the quarter, compared to analyst estimates of $670.24 million. STERIS plc had a net margin of 6.41% and a return on equity of 9.89%. The company’s revenue for the quarter was up 31.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.83 EPS. On average, equities analysts forecast that STERIS plc will post $3.90 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 21st. Investors of record on Wednesday, November 23rd will be issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a yield of 1.67%. The ex-dividend date of this dividend is Monday, November 21st. STERIS plc’s dividend payout ratio is presently 57.14%.
A number of research analysts have recently issued reports on the company. Zacks Investment Research upgraded STERIS plc from a “sell” rating to a “hold” rating in a research report on Tuesday. JMP Securities reiterated a “buy” rating on shares of STERIS plc in a research report on Friday, November 4th.
In related news, VP John Adam Zangerle sold 2,200 shares of the company’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $67.00, for a total transaction of $147,400.00. Following the transaction, the vice president now owns 26,166 shares of the company’s stock, valued at $1,753,122. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Martin Steeves sold 204,778 shares of the company’s stock in a transaction on Wednesday, September 7th. The stock was sold at an average price of $71.19, for a total value of $14,578,145.82. Following the transaction, the director now directly owns 165,434 shares in the company, valued at approximately $11,777,246.46. The disclosure for this sale can be found here. Corporate insiders own 2.52% of the company’s stock.
STERIS plc Company Profile
STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.